Adaptive Biotechnologies (NASDAQ:ADPT) CEO Chad Robins Sells 289,024 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 289,024 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $15.82, for a total value of $4,572,359.68. Following the completion of the sale, the chief executive officer owned 1,987,330 shares in the company, valued at $31,439,560.60. This represents a 12.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Adaptive Biotechnologies Trading Down 0.2%

Adaptive Biotechnologies stock opened at $16.08 on Wednesday. The stock has a 50-day moving average price of $16.85 and a 200 day moving average price of $15.79. Adaptive Biotechnologies Corporation has a 52 week low of $6.26 and a 52 week high of $20.76. The stock has a market cap of $2.48 billion, a PE ratio of -40.20 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. The company had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The firm’s quarterly revenue was up 51.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.23) EPS. On average, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Analysts Set New Price Targets

Several analysts have commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Wall Street Zen raised Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a research report on Friday, February 6th. Finally, Morgan Stanley started coverage on Adaptive Biotechnologies in a report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price target for the company. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $18.25.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. AQR Capital Management LLC boosted its holdings in Adaptive Biotechnologies by 45.8% in the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after acquiring an additional 97,444 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Adaptive Biotechnologies by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after purchasing an additional 2,914 shares during the period. Caxton Associates LLP acquired a new position in shares of Adaptive Biotechnologies in the 1st quarter valued at about $93,000. Envestnet Asset Management Inc. purchased a new stake in shares of Adaptive Biotechnologies during the 2nd quarter worth about $467,000. Finally, Versor Investments LP purchased a new stake in shares of Adaptive Biotechnologies during the 2nd quarter worth about $367,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.